Table I.
Baseline characterictics in the 1,501 nasopharyngeal carcinoma patients.
| CCRT patient PLT count (n=412) | RT patient PLT count (n=1089) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
||||||||
| Patient characteristic | Total patients, n (%)(n=1501) | Low, n (%) | Moderate, n (%) | High, n (%) | P-valuea | Low, n (%) | Moderate, n (%) | High, n (%) | P-valuea |
| Age, years | 0.326 | 0.289 | |||||||
| ≤45 | 734 (48.9) | 13 (41.9) | 163 (50.0) | 32 (58.2) | 52 (43.0) | 379 (48.2) | 95 (52.2) | ||
| >45 | 767 (51.1) | 18 (58.1) | 163 (50.0) | 23 (41.8) | 69 (57.0) | 407 (51.8) | 87 (47.8) | ||
| Gender | 0.044 | <0.001 | |||||||
| Male | 1158 (77.1) | 26 (83.9) | 271 (83.1) | 38 (69.1) | 99 (81.8) | 613 (78.0) | 111 (61.0) | ||
| Female | 343 (22.9) | 5 (16.1) | 55 (16.9) | 17 (30.9) | 22 (18.2) | 173 (22.0) | 71 (39.0) | ||
| Clinical stageb | 0.237 | 0.866 | |||||||
| I | 127 (8.5) | 2 (6.5) | 11 (3.4) | 2 (3.6) | 10 (8.3) | 85 (10.8) | 17 (9.3) | ||
| II | 583 (38.8) | 5 (16.1) | 93 (28.5) | 12 (21.8) | 53 (43.8) | 344 (43.8) | 76 (41.8) | ||
| III | 543 (36.2) | 17 (54.8) | 155 (47.5) | 22 (40.0) | 43 (35.5) | 247 (31.4) | 59 (32.4) | ||
| IV | 248 (16.5) | 7 (22.6) | 67 (20.6) | 19 (34.5) | 15 (12.4) | 110 (14.0) | 30 (16.5) | ||
| T stage | 0.101 | 0.619 | |||||||
| T1 | 326 (21.7) | 5 (16.1) | 59 (18.1) | 7 (12.7) | 24 (19.8) | 191 (24.3) | 40 (22.0) | ||
| T2 | 600 (40.0) | 12 (38.7) | 112 (34.4) | 14 (25.5) | 56 (46.3) | 333 (42.4) | 73 (40.1) | ||
| T3 | 360 (24.0) | 9 (29.0) | 101 (31.0) | 15 (27.3) | 26 (21.5) | 170 (21.6) | 39 (21.4) | ||
| T4 | 215 (14.3) | 5 (16.1) | 54 (16.6) | 19 (34.5) | 15 (12,4) | 92 (11.7) | 30 (16.5) | ||
| N stage | 0.134 | 0.111 | |||||||
| N0 | 466 (31.0) | 10 (32.3) | 52 (16.0) | 13 (23.6) | 49 (40.5) | 283 (36.0) | 59 (32.4) | ||
| N1 | 620 (41.3) | 8 (25.8) | 145 (44.5) | 20 (36.4) | 45 (37.2) | 323 (41.1) | 79 (43.4) | ||
| N2 | 376 (25.0) | 10 (32.3) | 114 (35.0) | 20 (36.4) | 27 (22.3) | 161 (20.5) | 44 (24.2) | ||
| N3 | 39 (2.6) | 3 (9.7) | 15 (4.6) | 2 (3.6) | 0 (0.0) | 19 (2.4) | 0 (0.0) | ||
| Treatment | |||||||||
| CCRT | 412 (27.4) | 31 (100.0) | 326 (100.0) | 55 (100.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
| RT | 1089 (72.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 121 (100.0) | 786 (100.0) | 182 (100.0) | ||
a
A χ2 test was performed to compare patient characteristics between the three PLT groups.
b
According to the seventh edition of the AJCC/UICC staging system (23).
CCRT, concurrent chemoradiotherapy; PLT, platelet; RT, radiotherapy alone; T, tumor; N, node.